DMN:FRA
Diamyd Medical AB
၀.၀၇၃ €
arrow_downward
-၀.၂၇%(-၀.၀၀၀၂၀) 1D
ဇွန် ၃၀, GMT+၂ ၂၂:၀၀:၀၀ · EUR
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for DMN...
Open
၀.၀၇ €
High
၀.၀၇ €
Low
၀.၀၇ €
Mkt. cap
၁၅.၄၅ ကုဋေ
Avg. vol.
၁၃၃.၀၀
Volume
၀.၀၀
52-wk high
၁.၈၀ €
52-wk low
၀.၀၅ €
No. of employees
၄၄
Open
၀.၀၇ €
High
၀.၀၇ €
Low
၀.၀၇ €
Mkt. cap
၁၅.၄၅ ကုဋေ
Avg. vol.
၁၃၃.၀၀
Volume
၀.၀၀
52-wk high
၁.၈၀ €
52-wk low
၀.၀၅ €
No. of employees
၄၄
News stories
From sources across the web
Stock Titan
·
ပြီးခဲ့သည့် ၃၄ မိနစ်
KORU Medical (NASDAQ: KRMD) extends Command supply deal to 2031
TheaterMania
·
ပြီးခဲ့သည့် ၁ နာရီ
André De Shields Rings the New York Stock Exchange Closing Bell
Yahoo Finance
·
ပြီးခဲ့သည့် ၅၂ မိနစ်
AI firm tied to bankrupt crypto lender files for Nasdaq listing
Investing.com
·
ပြီးခဲ့သည့် ၁၀ မိနစ်
Osprey Acquisition Corp. III prices $261M IPO on Nasdaq
Profile
Diamyd Medical AB is a small biotechnology company headquartered in Stockholm, Sweden that focuses on immune modifying therapies for type-1 diabetes. The company's investigational drug retogatein is based on a recombinant form of GAD₆₅, one of two human glutamate decarboxylase gene products.
The company is headquartered in Stockholm, and maintains a "biomanufacturing" facility in Umeå which utilizes bacuolavirus-mediated protein expression. Wikipedia
About Diamyd Medical AB
AI content may include mistakes. Learn more